Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2025 | Neflamapimod significantly lowers plasma GFAP in dementia with Lewy bodies: the RewinD-LB trial

Charlotte Teunissen • 27 Nov 2025
CTAD 2025
Dementia Dementia with Lewy Bodies Neflamapimod

Charlotte Teunissen, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands, discusses results from the Phase II RewinD-LB trial (NCT05869669) of neflamapimod in dementia with Lewy bodies. Prof. Teunissen highlights that neflamapimod significantly lowered plasma GFAP levels and correlated with a clinical benefit. This interview took place at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Charlotte Teunissen

Diagnostic performance of novel plasma assays for detecting AD pathology across the disease spectrum 5:52
Diagnostic performance of novel plasma assays for detecting AD pathology across the disease spectrum
Charlotte Teunissen • 27 Nov 2025
Early predictive value of plasma biomarkers for amyloid positivity 2:19
Early predictive value of plasma biomarkers for amyloid positivity
Charlotte Teunissen • 10 Aug 2022
Fluid biomarkers of immune function in Alzheimer’s disease 2:24
Fluid biomarkers of immune function in Alzheimer’s disease
Charlotte Teunissen • 10 Aug 2022
Blood biomarkers in AD: latest data, establishing SOPs, and new appropriate use guidelines 10:02
Blood biomarkers in AD: latest data, establishing SOPs, and new appropriate use guidelines
Charlotte Teunissen • 10 Aug 2022

Related Videos

Diagnostic performance of novel plasma assays for detecting AD pathology across the disease spectrum 5:52
Diagnostic performance of novel plasma assays for detecting AD pathology across the disease spectrum
Charlotte Teunissen • 27 Nov 2025
Targeting cPLA2 to address the lack of response to omega-3s in patients with AD who are E4 carriers 3:05
Targeting cPLA2 to address the lack of response to omega-3s in patients with AD who are E4 carriers
Hussein Yassine • 27 Nov 2025
Phase I findings of ABCA-1 agonist treatment with CS6253 in older adults: potential treatment for AD 1:33
Phase I findings of ABCA-1 agonist treatment with CS6253 in older adults: potential treatment for AD
Hussein Yassine • 27 Nov 2025
Emerging therapies targeting APOE for the treatment of Alzheimer’s disease 1:42
Emerging therapies targeting APOE for the treatment of Alzheimer’s disease
Hussein Yassine • 27 Nov 2025
The content of VJDementia is intended for healthcare professionals